Nocodazole
Based on 126 publication(s) in Google Scholar
Nocodazole (Oncodazole) is a rapidly-reversible inhibitor of microtubule. Nocodazole binds to β-tubulin and disrupts microtubule assembly/disassembly dynamics, which prevents mitosis and induces apoptosis in tumor cells. Nocodazole inhibits Bcr-Abl.
For research use only. We do not sell to patients.
- Purity: 99.59%
- CAS No.: 31430-18-9
- Formula: C14H11N3O3S
- Molecular Weight:301.32
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Nocodazole
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Science. 2022 Nov 18;378(6621):eabq7361. [Abstract]
- Cell. 2025 Jun 26;188(13):3405-3421.e27. [Abstract]
- Nat Methods. 2022 Mar;19(3):331-340. [Abstract]
- Adv Mater. 2025 Jan 10:e2415030. [Abstract]
- Adv Mater. 2022 Jul 28;e2204287. [Abstract]
- Cancer Commun (Lond). 2025 Oct 16. [Abstract]
- Adv Fiber Mater. 2026 Mar 21.
- Sci Bull. 2025 Aug 11:S2095-9273(25)00813-8. [Abstract]
- Cell Mol Immunol. 2020 May;17(5):496-506. [Abstract]
- ACS Nano. 2026 Apr 21;20(15):11887-11898. [Abstract]
- ACS Nano. 2024 Sep 17;18(37):25893-25905. [Abstract]
- ACS Nano. 2024 Jan 23;18(3):2162-2183. [Abstract]
- ACS Nano. 2023 Sep 26;17(18):18548-18561. [Abstract]
- Nat Commun. 2026 Jun 8. [Abstract]
- Nat Commun. 2026 Mar 17;17(1):2049. [Abstract]
- Nat Commun. 2024 Nov 12;15(1):9529. [Abstract]
- Nat Commun. 2023 May 26;14(1):3050. [Abstract]
- Nat Commun. 2022 Oct 12;13(1):6004. [Abstract]
- Nat Commun. 2019 Jun 28;10(1):2860. [Abstract]
- Cell Death Differ. 2023 Apr;30(4):922-937. [Abstract]
- Trends Biotechnol. 2025 Aug 30:S0167-7799(25)00314-2. [Abstract]
- Autophagy. 2021 Dec;17(12):3976-3991. [Abstract]
- Adv Sci (Weinh). 2026 Jun;13(34):e01083. [Abstract]
- Adv Sci (Weinh). 2025 Sep 3:e02788. [Abstract]
- Adv Sci (Weinh). 2024 Dec 4:e2408852. [Abstract]
- Adv Sci (Weinh). 2024 Oct 23:e2401842. [Abstract]
- Adv Sci (Weinh). 2024 Dec;11(45):e2405441. [Abstract]
- Adv Sci (Weinh). 2020 Jun 17;7(15):1903583. [Abstract]
- Theranostics. 2019 May 31;9(13):3732-3753. [Abstract]
- Theranostics. 2019 Apr 13;9(9):2555-2571. [Abstract]
- Chem Eng J. 2025 Jul 1.
- Nucleic Acids Res. 2020 Dec 16;48(22):e127. [Abstract]
- Cell Discov. 2024 Nov 5;10(1):112. [Abstract]
- Carbohydr Polym. 2025 Jan 15;348(Pt A):122854. [Abstract]
- Redox Biol. 2025 May:82:103581. [Abstract]
- J Control Release. 2025 Mar 24:113660. [Abstract]
- J Control Release. 2025 Jan 8:379:45-58. [Abstract]
- J Immunother Cancer. 2024 Dec 18;12(12):e009444. [Abstract]
- Mater Today Bio. 2025 May 10:32:101838. [Abstract]
- Cell Mol Biol Lett. 2024 Sep 27;29(1):124. [Abstract]
- Cell Mol Biol Lett. 2023 Oct 27;28(1):87. [Abstract]
- J Neuroinflammation. 2022 Feb 22;19(1):53. [Abstract]
- Cell Death Dis. 2025 Sep 29;16(1):673. [Abstract]
- Cell Death Dis. 2024 Jan 11;15(1):35. [Abstract]
- Cell Death Dis. 2022 Mar 30;13(3):284. [Abstract]
- Sci China Life Sci. 2025 Aug;68(8):2348-2362. [Abstract]
- Cell Commun Signal. 2025 Jul 1;23(1):306. [Abstract]
- Dev Cell. 2025 Jun 23;60(12):1751-1767.e9. [Abstract]
- Int J Biol Macromol. 2025 Jan 20:140112. [Abstract]
- Int J Biol Macromol. 2024 Jan;256(Pt 1):128336. [Abstract]
- Acta Pharmacol Sin. 2024 Nov;45(11):2420-2431. [Abstract]
- ACS Appl Mater Interfaces. 2026 Apr 22;18(15):21500-21513. [Abstract]
- ACS Appl Mater Interfaces. 2025 Mar 19;17(11):16533-16547. [Abstract]
- Cancer Immunol Res. 2023 May 3;11(5):583-599. [Abstract]
- Free Radic Biol Med. 2023 Feb 20:196:53-64. [Abstract]
- Mater Sci Eng C Mater Biol Appl. 2021 Mar:122:111939. [Abstract]
- NPJ Precis Oncol. 2025 Dec 10. [Abstract]
- ACS Environ Au. 2025 Aug 5;5(6):573-582. [Abstract]
- Genes Dev. 2021 Oct 1;35(19-20):1327-1332. [Abstract]
- Biomed Pharmacother. 2025 Nov 6:193:118716. [Abstract]
- Biomed Pharmacother. 2023 Oct:166:115389. [Abstract]
- Int Endod J. 2026 Jun 2. [Abstract]
- Aging Cell. 2026 Feb;25(2):e70402. [Abstract]
- Int Endod J. 2025 Apr 1. [Abstract]
- Cell Rep. 2024 Jul 3;43(7):114431. [Abstract]
- Cell Rep. 2019 Jan 2;26(1):209-221.e5. [Abstract]
- Clin Transl Med. 2025 Jan;15(1):e70193. [Abstract]
- Anal Chem. 2025 Oct 28;97(42):23251-23259. [Abstract]
- Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]
- Anal Chem. 2023 May 23;95(20):8088-8096. [Abstract]
- Sci Signal. 2025 Mar 18;18(878):eadi5174. [Abstract]
- J Cell Biol. 2026 Jun 1;225(6):e202502001. [Abstract]
- Cell Biosci. 2023 Nov 25;13(1):215. [Abstract]
- JCI Insight. 2021 Sep 22;6(18):e148931. [Abstract]
- Cell Prolif. 2025 Jan 27:e13811. [Abstract]
- Pharmaceutics. 2020 Feb 17;12(2):167. [Abstract]
- PLoS Pathog. 2021 Aug 9;17(8):e1009838. [Abstract]
- Int Immunopharmacol. 2024 Jun 29:138:112549. [Abstract]
- Mol Cancer Res. 2023 Aug 1;21(8):768-778. [Abstract]
- J Mol Cell Cardiol. 2022 Dec:173:101-114. [Abstract]
- Bioelectrochemistry. 2016 Jun:109:31-40. [Abstract]
- Mol Nutr Food Res. 2023 Jun;67(12):e2200784. [Abstract]
- J Cell Mol Med. 2021 Sep;25(18):8821-8835. [Abstract]
- J Cell Mol Med. 2021 Jun;25(11):5202-5219. [Abstract]
- iScience. 2026 Mar 4;29(4):115223. [Abstract]
- AAPS PharmSciTech. 2023 Feb 15;24(2):69. [Abstract]
- J Dermatol Sci. 2022 Jun;106(3):181-188. [Abstract]
- J Virol. 2025 Apr 30:e0007825. [Abstract]
- Reproduction. 2026 Jan 15;171(1):xaaf013. [Abstract]
- Chemistry. 2025 May 23:e202501329. [Abstract]
- Food Chem Toxicol. 2023 Sep:179:113966. [Abstract]
- Cell Cycle. 2019 May;18(9):1019-1032. [Abstract]
- Biochim Biophys Acta Mol Cell Biol Lipids. 2025 Apr 4:159610. [Abstract]
- J Cancer. 2022 Jan 24;13(4):1229-1240. [Abstract]
- Hum Mol Genet. 2022 Jun 22;31(12):2035-2048. [Abstract]
- Front Biosci (Landmark Ed). 2025 Jan 21;30(1):26426. [Abstract]
- Toxicol In Vitro. 2024 Jun:98:105834. [Abstract]
- Virus Res. 2020 Jan 15;276:197806. [Abstract]
- PLoS One. 2019 Jul 3;14(7):e0210377. [Abstract]
- Dig Dis Sci. 2024 Jul;69(7):2462-2476. [Abstract]
- Biochem Biophys Res Commun. 2025 Sep 30:782:152552. [Abstract]
- J Mol Histol. 2025 Feb 4;56(2):79. [Abstract]
- Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868. [Abstract]
- Biol Open. 2019 Aug 15;8(8):bio041293. [Abstract]
- bioRxiv. 2026 Mar 15.
- SSRN. 2025 Sep 30.
- bioRxiv. 2025 Sep 18:2025.09.17.676776. [Abstract]
- bioRxiv. 2025 Sep 15.
- bioRxiv. 2025 Jul 21.
- bioRxiv. 2025 Jun 17:2025.06.16.659978. [Abstract]
- bioRxiv. 2025 May 09.
- bioRxiv. 2025 Apr 7:2025.04.06.647500. [Abstract]
- bioRxiv. 2025 April 10.
- bioRxiv. 2025 Feb 8:2025.02.07.637094. [Abstract]
- bioRxiv. 2024 Aug 21:2024.08.20.608802. [Abstract]
- Res Sq. 2024 Jul 12.
- bioRxiv. 2024 Jul 27:2024.07.25.605164. [Abstract]
- bioRxiv. 2024 June 16.
- Smart Mater Med. 2023 Jun 10.
- Research Square Print. 2023 Mar 21.
- bioRxiv. 2023 Jan 25.
- Research Square Preprint. 2022 May.
- Research Square Preprint. 2021 Jun.
- bioRxiv. 2021 Feb 1.
- bioRxiv. September 11, 2018.
-
WB
-
WB
-
IF
-
WB
-
RT-PCR
Biological Activity
|
Abl 91 nM (Kd) |
ABL(E255K) 120 nM (Kd) |
ABL(T315I) 170 nM (Kd) |
BRAF 1.8 μM (Kd) |
BRAF(V600E) 1.1 μM (Kd) |
c-KIT 1.6 μM (Kd) |
MEK1 1.7 μM (Kd) |
MEK2 1.6 μM (Kd) |
MET 1.7 μM (Kd) |
PI3Kγ 1.5 μM (Kd) |
Microtubule/Tubulin |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 4T1 | IC50 |
1.3 μM
Compound: Nocodazole
|
Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay
Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay
|
[PMID: 27496212] |
| A-375 | IC50 |
0.2 μM
Compound: Nocodazole
|
Anticancer activity against human A375 cells by MTT assay
Anticancer activity against human A375 cells by MTT assay
|
10.1039/C4MD00219A |
| A549 | EC50 |
106.5 nM
Compound: Nocodazole
|
Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by flow cytometry
Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by flow cytometry
|
[PMID: 20110137] |
| A549 | GI50 |
<0.01 μM
Compound: Nocodazole
|
Antiproliferative activity against human A549 cells after 48 hrs by SRB cell proliferation assay
Antiproliferative activity against human A549 cells after 48 hrs by SRB cell proliferation assay
|
[PMID: 29089233] |
| A549 | GI50 |
<0.1 μM
Compound: Nocodozole
|
Growth inhibition of human A549 cells by Sulforhodamine B assay
Growth inhibition of human A549 cells by Sulforhodamine B assay
|
[PMID: 21106458] |
| A549 | GI50 |
0.02 μM
Compound: Nocadazole
|
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 25827522] |
| A549 | GI50 |
0.08 μM
Compound: Nocodazole
|
Anticancer activity against human A549 cells after 48 hrs by SRB assay
Anticancer activity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 27130357] |
| A549 | GI50 |
0.09 μM
Compound: Nocodazole
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 28117204] |
| A549 | GI50 |
0.21 μM
Compound: Nocodazole
|
Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay
|
10.1039/C0MD00177E |
| A549 | GI50 |
0.5 μM
Compound: Nocodozole
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 20529689] |
| A549 | IC50 |
<0.1 μM
Compound: Nocodazole
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay
|
10.1039/C0MD00263A |
| A549 | IC50 |
0.087 μM
Compound: Nocodazole
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 21954851] |
| A549 | IC50 |
0.12 μM
Compound: 1
|
Growth inhibition of human A549 cells after 72 hrs by MTT assay
Growth inhibition of human A549 cells after 72 hrs by MTT assay
|
[PMID: 25262051] |
| A549 | IC50 |
0.13 μM
Compound: 4
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
10.1039/C5MD00150A |
| A549 | IC50 |
0.2 μM
Compound: Ncz
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30878833] |
| A549 | IC50 |
0.272 μM
Compound: Nocodazole
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by CellTiter96 Aqueous one solution cell proliferation assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by CellTiter96 Aqueous one solution cell proliferation assay
|
[PMID: 32551013] |
| A549 | IC50 |
0.82 μM
Compound: 2
|
Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 30108808] |
| A549 | IC50 |
0.89 μM
Compound: Nocodazole
|
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25599948] |
| A549 | IC50 |
0.9 μM
Compound: Nocodazole
|
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 28988624] |
| A549 | IC50 |
1.05 μM
Compound: 3
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 30108921] |
| A549 | IC50 |
1.14 μM
Compound: Nocodazole
|
Antiproliferative activity human A549 cells
Antiproliferative activity human A549 cells
|
[PMID: 33316752] |
| A549 | IC50 |
1.38 μM
Compound: Nacodazole
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31546197] |
| A549 | IC50 |
1.393 μM
Compound: Nocodazole
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 30108815] |
| A549 | IC50 |
1.513 μM
Compound: Nocodazole
|
Anticancer activity against human A549 cells after 48 hrs by MTT assay
Anticancer activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 28789894] |
| A549 | IC50 |
1.62 μM
Compound: Nocodazole
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
10.1039/C4MD00400K |
| A549 | IC50 |
1.807 μM
Compound: Nocodazole
|
Cytotoxicity against human A549 cells assessed as inhibition of cell growth by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 31926469] |
| A549 | IC50 |
1.807 μM
Compound: Nocodazole
|
Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay
|
[PMID: 33316752] |
| A549 | IC50 |
1.87 μM
Compound: Nocodazole
|
Anticancer activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
Anticancer activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
|
[PMID: 26231080] |
| A549 | IC50 |
1.87 μM
Compound: Nocodazole
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 28668476] |
| A549 | IC50 |
2.3 μM
Compound: Nocodazole
|
Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 28684120] |
| A549 | IC50 |
2.31 μM
Compound: nocodazole
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 23748152] |
| A549 | IC50 |
2.5 μM
Compound: Nocodazole
|
Anticancer activity against human A549 cells by MTT assay
Anticancer activity against human A549 cells by MTT assay
|
10.1039/C4MD00219A |
| A549 | IC50 |
3.63 μM
Compound: Nocodazole
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32717368] |
| A549 | IC50 |
36.6 nM
Compound: Nocodazole
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 20110137] |
| A549 | IC50 |
5.09 μM
Compound: 68
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38784470] |
| A549 | IC50 |
5.93 μM
Compound: NDZ
|
Anticancer activity against human A549 cells assessed as inhibition in cell growth measured after 72 hrs by MTT assay
Anticancer activity against human A549 cells assessed as inhibition in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37797804] |
| B16 | IC50 |
0.1 μM
Compound: 1
|
Inhibition B16 melanoma cell monolayer proliferation
Inhibition B16 melanoma cell monolayer proliferation
|
[PMID: 2913301] |
| B16 | IC50 |
0.69 μM
Compound: Nocodazole
|
Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
|
10.1039/C4MD00400K |
| B16-F10 | IC50 |
3.12 μM
Compound: Nocodazole
|
Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32717368] |
| B16-F10 | IC50 |
8.58 μM
Compound: NDZ
|
Anticancer activity against mouse B16-F10 cells assessed as inhibition in cell growth measured after 72 hrs by MTT assay
Anticancer activity against mouse B16-F10 cells assessed as inhibition in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37797804] |
| BT-474 | IC50 |
0.87 μM
Compound: Nocodazole
|
Cytotoxicity against human BT-474 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human BT-474 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 34095841] |
| BT-474 | IC50 |
2.72 μM
Compound: Nocodazole
|
Cytotoxicity against human BT-474 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human BT-474 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32717368] |
| BT-549 | IC50 |
0.069 μM
Compound: Nocodazole
|
Antiproliferative activity against human BT549 cells after 48 hrs by alamar blue assay
Antiproliferative activity against human BT549 cells after 48 hrs by alamar blue assay
|
[PMID: 21563750] |
| CAL-51 | GI50 |
0.209 μM
Compound: Nocodazole
|
Antiproliferative activity against human CAL-51 cells incubated for 72 hrs by SRB proliferation assay
Antiproliferative activity against human CAL-51 cells incubated for 72 hrs by SRB proliferation assay
|
[PMID: 37849542] |
| CAPAN-1 | IC50 |
0.13 μM
Compound: Nocodazole
|
Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
|
[PMID: 37252100] |
| COLO 205 | IC50 |
0.088 μM
Compound: Nocodazole
|
Antiproliferative activity against human COLO205 cells after 48 hrs by alamar blue assay
Antiproliferative activity against human COLO205 cells after 48 hrs by alamar blue assay
|
[PMID: 21563750] |
| Cortical neurone | IC50 |
0.097 μM
Compound: Nocodazole
|
Neurotoxicity in rat cortical neuron assessed as inhibition of neurite outgrowth by measuring mean neurite average length incubated for 72 hrs by Hoechst 33342 staining based ArrayScan analysis
Neurotoxicity in rat cortical neuron assessed as inhibition of neurite outgrowth by measuring mean neurite average length incubated for 72 hrs by Hoechst 33342 staining based ArrayScan analysis
|
[PMID: 31841637] |
| Cortical neurone | IC50 |
0.0997 μM
Compound: Nocodazole
|
Neurotoxicity in rat cortical neuron assessed as inhibition of neurite total length per neuron incubated for 72 hrs by Hoechst 33342 staining based ArrayScan analysis
Neurotoxicity in rat cortical neuron assessed as inhibition of neurite total length per neuron incubated for 72 hrs by Hoechst 33342 staining based ArrayScan analysis
|
[PMID: 31841637] |
| Cortical neurone | IC50 |
2.22 μM
Compound: Nocodazole
|
Neurotoxicity in rat cortical neuron assessed as inhibition of valid neuron count incubated for 72 hrs by Hoechst 33342 staining based ArrayScan analysis
Neurotoxicity in rat cortical neuron assessed as inhibition of valid neuron count incubated for 72 hrs by Hoechst 33342 staining based ArrayScan analysis
|
[PMID: 31841637] |
| DLD-1 | IC50 |
0.19 μM
Compound: Nocodazole
|
Antiproliferative activity against human DLD1 cells after 48 hrs by alamar blue assay
Antiproliferative activity against human DLD1 cells after 48 hrs by alamar blue assay
|
[PMID: 21563750] |
| DU-145 | GI50 |
0.011 μM
Compound: Nacodazole
|
Antiproliferative activity against human DU145 cells by SRB assay
Antiproliferative activity against human DU145 cells by SRB assay
|
[PMID: 31546197] |
| DU-145 | GI50 |
0.19 μM
Compound: Nocodazole
|
Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay
|
10.1039/C0MD00177E |
| DU-145 | IC50 |
<0.1 μM
Compound: Nocodazole
|
Cytotoxicity against human DU145 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human DU145 cells assessed as growth inhibition after 48 hrs by SRB assay
|
10.1039/C0MD00263A |
| DU-145 | IC50 |
0.25 μM
Compound: Nocodazole
|
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
|
10.1039/C4MD00400K |
| DU-145 | IC50 |
1.14 μM
Compound: Nocodazole
|
Cytotoxicity in human DU145 cells incubated for 48 hrs by MTT assay
Cytotoxicity in human DU145 cells incubated for 48 hrs by MTT assay
|
[PMID: 28923381] |
| DU-145 | IC50 |
1.259 μM
Compound: Nocodazole
|
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 30108815] |
| DU-145 | IC50 |
1.38 μM
Compound: Nacodazole
|
Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31546197] |
| DU-145 | IC50 |
1.39 μM
Compound: 3
|
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 30108921] |
| DU-145 | IC50 |
1.698 μM
Compound: Nocodazole
|
Anticancer activity against human DU145 cells after 48 hrs by MTT assay
Anticancer activity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 28789894] |
| DU-145 | IC50 |
2.1 μM
Compound: Nocodazole
|
Anticancer activity against human DU145 cells by MTT assay
Anticancer activity against human DU145 cells by MTT assay
|
10.1039/C4MD00219A |
| DU-145 | IC50 |
2.2 μM
Compound: Nocodazole
|
Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay
|
[PMID: 27496212] |
| DU-145 | IC50 |
2.8 μM
Compound: nocodazole
|
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 23748152] |
| DU-145 | IC50 |
3.2 μM
Compound: Nocodazole
|
Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25599948] |
| HaCaT | IC50 |
1.19 μM
Compound: Nocodazole
|
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 34095841] |
| HaCaT | IC50 |
8.9 μM
Compound: Nocodazole
|
Cytotoxic activity against human HaCaT cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
Cytotoxic activity against human HaCaT cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
|
[PMID: 26231080] |
| HCT-116 | GI50 |
0.24 μM
Compound: Nocodazole
|
Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by SRB proliferation assay
Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by SRB proliferation assay
|
[PMID: 37849542] |
| HCT-116 | IC50 |
0.13 μM
Compound: Nocodazole
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
|
[PMID: 37252100] |
| HCT-116 | IC50 |
0.173 μM
Compound: Nocodazole
|
Cytotoxicity against human HCT116 cells by SRB assay
Cytotoxicity against human HCT116 cells by SRB assay
|
[PMID: 21954851] |
| HCT-116 | IC50 |
1.06 μM
Compound: Nocodazole
|
Cytotoxicity in human HCT116 cells incubated for 48 hrs by MTT assay
Cytotoxicity in human HCT116 cells incubated for 48 hrs by MTT assay
|
[PMID: 28923381] |
| HCT-116 | IC50 |
1.262 μM
Compound: Nocodazole
|
Anticancer activity against human HCT116 cells after 48 hrs by MTT assay
Anticancer activity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 28789894] |
| HCT-116 | IC50 |
1.38 μM
Compound: Nacodazole
|
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31546197] |
| HCT-116 | IC50 |
1.81 μM
Compound: 68
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38784470] |
| HCT-116 | IC50 |
2.82 μM
Compound: Nocodazole
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32717368] |
| HCT-116 | IC50 |
3.5 μM
Compound: NDZ
|
Anticancer activity against human HCT-116 cells assessed as inhibition in cell growth measured after 72 hrs by MTT assay
Anticancer activity against human HCT-116 cells assessed as inhibition in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37797804] |
| HEK293 | IC50 |
2.2 μM
Compound: Nacodazole
|
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31546197] |
| HEK293 | IC50 |
5.1 μM
Compound: Nocodazole
|
Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 24 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 24 hrs by MTT assay
|
[PMID: 27496212] |
| HeLa | EC50 |
40 nM
Compound: Nocodazole
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell growth after 48 hrs by resazurin dye based fluorescence assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell growth after 48 hrs by resazurin dye based fluorescence assay
|
[PMID: 31735573] |
| HeLa | GI50 |
<0.01 μM
Compound: Nacodazole
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 31546197] |
| HeLa | GI50 |
<0.01 μM
Compound: Nocodazole
|
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 27688193] |
| HeLa | GI50 |
<0.01 μM
Compound: Nocodazole
|
Antiproliferative activity against human HeLa cells after 48 hrs by SRB cell proliferation assay
Antiproliferative activity against human HeLa cells after 48 hrs by SRB cell proliferation assay
|
[PMID: 29089233] |
| HeLa | GI50 |
0.011 μM
Compound: Nacodazole
|
Antiproliferative activity against human HeLa cells by SRB assay
Antiproliferative activity against human HeLa cells by SRB assay
|
[PMID: 31546197] |
| HeLa | GI50 |
0.015 μM
Compound: Nocadazole
|
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 25827522] |
| HeLa | GI50 |
0.063 μM
Compound: Nocodazole
|
Anticancer activity against human HeLa cells after 48 hrs by SRB assay
Anticancer activity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 27130357] |
| HeLa | GI50 |
0.086 μM
Compound: Nocodazole
|
Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 28117204] |
| HeLa | GI50 |
0.75 μM
Compound: Nocodazole
|
Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay
|
10.1039/C0MD00177E |
| HeLa | GI50 |
0.75 μM
Compound: Nocodozole
|
Growth inhibition of human HeLa cells by Sulforhodamine B assay
Growth inhibition of human HeLa cells by Sulforhodamine B assay
|
[PMID: 21106458] |
| HeLa | GI50 |
0.81 μM
Compound: 6
|
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 25131956] |
| HeLa | GI50 |
0.81 μM
Compound: Nocodazole
|
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 27344493] |
| HeLa | IC50 |
0.3 μM
Compound: Ncz
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30878833] |
| HeLa | IC50 |
0.71 μM
Compound: nocodazole
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 23748152] |
| HeLa | IC50 |
0.84 μM
Compound: 2
|
Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay
|
[PMID: 30108808] |
| HeLa | IC50 |
1.05 μM
Compound: 3
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 30108921] |
| HeLa | IC50 |
1.1 μM
Compound: Nocodazole
|
Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25599948] |
| HeLa | IC50 |
1.11 μM
Compound: Nocodazole
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 34095841] |
| HeLa | IC50 |
1.2 μM
Compound: Nocodazole
|
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 28988624] |
| HeLa | IC50 |
1.6 μM
Compound: Nocodazole
|
Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay
|
[PMID: 28684120] |
| HeLa | IC50 |
1.611 μM
Compound: Nocodazole
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 30108815] |
| HeLa | IC50 |
178 nM
Compound: Nocodazole
|
Cytotoxicity against human HeLa cells after 24 to 48 hrs by trypan blue assay
Cytotoxicity against human HeLa cells after 24 to 48 hrs by trypan blue assay
|
[PMID: 23445405] |
| HeLa | IC50 |
2.22 μM
Compound: 68
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38784470] |
| HeLa | IC50 |
2.23 μM
Compound: Nocodazole
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
10.1039/C4MD00400K |
| HeLa | IC50 |
2.83 μM
Compound: Nocodazole
|
Anticancer activity against human HeLa cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
Anticancer activity against human HeLa cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
|
[PMID: 26231080] |
| HeLa | IC50 |
2.83 μM
Compound: Nocodazole
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 28668476] |
| HepG2 | GI50 |
<0.01 μM
Compound: Nacodazole
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 31546197] |
| HepG2 | GI50 |
0.011 μM
Compound: Nacodazole
|
Antiproliferative activity against human HepG2 cells by SRB assay
Antiproliferative activity against human HepG2 cells by SRB assay
|
[PMID: 31546197] |
| HepG2 | GI50 |
0.76 μM
Compound: Nocodazole
|
Growth inhibition of human HepG2 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human HepG2 cells after 48 hrs by sulforhodamine B assay
|
10.1039/C0MD00177E |
| HepG2 | IC50 |
<0.1 μM
Compound: Nocodazole
|
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by SRB assay
|
10.1039/C0MD00263A |
| HepG2 | IC50 |
0.4 μM
Compound: Ncz
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30878833] |
| HepG2 | IC50 |
1.1 μM
Compound: Nocodazole
|
Antiproliferative activity against human HepG2 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HepG2 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 28684120] |
| HepG2 | IC50 |
5.08 μM
Compound: 68
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38784470] |
| HL-60 | IC50 |
0.1 μM
Compound: Nocodazole
|
Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
|
[PMID: 37252100] |
| HMEC | IC50 |
11.5 μM
Compound: Ncz
|
Antiproliferative activity against human HMEC cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HMEC cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30878833] |
| HT-1080 | IC50 |
0.14 μM
Compound: 1
|
Growth inhibition of human HT1080 cells after 72 hrs by MTT assay
Growth inhibition of human HT1080 cells after 72 hrs by MTT assay
|
[PMID: 25262051] |
| HT-1080 | IC50 |
0.15 μM
Compound: 4
|
Antiproliferative activity against human HT1080 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human HT1080 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
10.1039/C5MD00150A |
| HT-29 | IC50 |
2.2 μM
Compound: Nacodazole
|
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31546197] |
| IMR-32 | GI50 |
<0.01 μM
Compound: Nacodazole
|
Antiproliferative activity against human IMR32 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Antiproliferative activity against human IMR32 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 31546197] |
| IMR-32 | IC50 |
1.3 μM
Compound: Nocodazole
|
Antiproliferative activity against human IMR32 cells after 48 hrs by SRB assay
Antiproliferative activity against human IMR32 cells after 48 hrs by SRB assay
|
[PMID: 28988624] |
| K562 | EC50 |
0.082 μM
Compound: Nocodazole
|
Effective concentration required to arrest propidium iodide stained K562 cells in G2/M phase
Effective concentration required to arrest propidium iodide stained K562 cells in G2/M phase
|
[PMID: 12852768] |
| K562 | IC50 |
0.07 μM
Compound: Nocodazole
|
Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
|
[PMID: 37252100] |
| K562 | IC50 |
0.22 μM
Compound: Nocodazole
|
Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 33212157] |
| K562 | IC50 |
0.76 μM
Compound: Nocodazole
|
Inhibition of tubulin polymerization in human K562 cells
Inhibition of tubulin polymerization in human K562 cells
|
[PMID: 20546980] |
| KB | EC50 |
91 nM
Compound: nocodazole
|
Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase
Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase
|
[PMID: 17181164] |
| KB | EC50 |
91 nM
Compound: nocodazole
|
Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometric analysis
Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometric analysis
|
[PMID: 17973361] |
| KB | EC50 |
91 nM
Compound: nocodazole
|
Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation after 24 hrs by FACS analysis
Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation after 24 hrs by FACS analysis
|
[PMID: 19220018] |
| KB | EC50 |
91 nM
Compound: Nocodazole
|
Cell cycle arrest in human KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis
Cell cycle arrest in human KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis
|
[PMID: 20537765] |
| KB | EC50 |
91 nM
Compound: Nocodazole
|
Cell cycle arrest in human KB/HeLa cells assessed as accumulation of cells at G2/M phase after 24 hrs by flow cytometry
Cell cycle arrest in human KB/HeLa cells assessed as accumulation of cells at G2/M phase after 24 hrs by flow cytometry
|
[PMID: 21705223] |
| KB | IC50 |
0.14 μM
Compound: Nocodazole
|
Cytotoxic activity against cellular metabolic activity of Cervix KB/HeLa tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
Cytotoxic activity against cellular metabolic activity of Cervix KB/HeLa tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
|
[PMID: 12852768] |
| KB | IC50 |
0.14 μM
Compound: nocodazole
|
Antiproliferative activity against KB/HeLa cells by XTT assay after 48 hrs
Antiproliferative activity against KB/HeLa cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| KB | IC50 |
0.14 μM
Compound: nocodazole
|
Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay
Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay
|
[PMID: 17973361] |
| KB | IC50 |
0.14 μM
Compound: nocodazole
|
Antiproliferative activity against human KB/HeLa cells by XTT assay
Antiproliferative activity against human KB/HeLa cells by XTT assay
|
[PMID: 19220018] |
| KB | IC50 |
0.14 μM
Compound: Nocodazole
|
Antiproliferative activity against human KB/HeLa cells after 48 hrs by XTT assay
Antiproliferative activity against human KB/HeLa cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| KB | IC50 |
0.14 μM
Compound: Nocodazole
|
Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay
Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay
|
[PMID: 21705223] |
| L02 | IC50 |
13.5 μM
Compound: Ncz
|
Antiproliferative activity against human HL7702 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HL7702 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30878833] |
| L1210 | IC50 |
>5 μM
Compound: nocodazole
|
Antiproliferative activity against vincristine-resistance MRP1 negative mouse L1210 cells expressing human MDR1 after 48 hrs by XTT assay
Antiproliferative activity against vincristine-resistance MRP1 negative mouse L1210 cells expressing human MDR1 after 48 hrs by XTT assay
|
[PMID: 19220018] |
| L1210 | IC50 |
0.038 μM
Compound: Nocodazole
|
In vitro for its inhibitory activity against L1210 murine leukemia cell growth
In vitro for its inhibitory activity against L1210 murine leukemia cell growth
|
[PMID: 1738146] |
| L1210 | IC50 |
0.05 μM
Compound: nocodazole
|
Antiproliferative activity against L1210 cells by XTT assay after 48 hrs
Antiproliferative activity against L1210 cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| L1210 | IC50 |
0.05 μM
Compound: Nocodazole
|
Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| L1210 | IC50 |
0.06 μM
Compound: nocodazole
|
Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
|
[PMID: 17973361] |
| L1210 | IC50 |
0.06 μM
Compound: nocodazole
|
Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
|
[PMID: 19220018] |
| L1210 | IC50 |
0.06 μM
Compound: Nocodazole
|
Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
|
[PMID: 21705223] |
| L1210 | IC50 |
0.06 μM
Compound: Nocodazole
|
Antiproliferative activity against L1210 tumor cell line
Antiproliferative activity against L1210 tumor cell line
|
[PMID: 12852768] |
| L1210 | IC50 |
0.07 μM
Compound: nocodazole
|
Antiproliferative activity against mouse vincristine-resistant L1210 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse vincristine-resistant L1210 cells after 48 hrs by XTT assay
|
[PMID: 17973361] |
| L1210 | IC50 |
0.07 μM
Compound: Nocodazole
|
Antiproliferative activity against mouse VCR-resistant L1210 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse VCR-resistant L1210 cells after 48 hrs by XTT assay
|
[PMID: 21705223] |
| L1210 | IC50 |
0.07 μM
Compound: Nocodazole
|
Antiproliferative activity against L1210 phenotype L1210 VCR tumor cell line
Antiproliferative activity against L1210 phenotype L1210 VCR tumor cell line
|
[PMID: 12852768] |
| L1210 | IC50 |
0.09 μM
Compound: nocodazole
|
Antiproliferative activity against L1210 VCR cells by XTT assay after 48 hrs
Antiproliferative activity against L1210 VCR cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| L1210 | IC50 |
0.09 μM
Compound: Nocodazole
|
Antiproliferative activity against vincristine-resistant mouse L1210 cells after 48 hrs by XTT assay
Antiproliferative activity against vincristine-resistant mouse L1210 cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| LN-229 | IC50 |
0.1 μM
Compound: Nocodazole
|
Antiproliferative activity against human LN-229 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
Antiproliferative activity against human LN-229 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
|
[PMID: 37252100] |
| LT12 tumor cell line | IC50 |
0.006 μM
Compound: nocodazole
|
Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay
Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay
|
[PMID: 19220018] |
| LT12 tumor cell line | IC50 |
0.04 μM
Compound: nocodazole
|
Antiproliferative activity against LT12 cells by XTT assay after 48 hrs
Antiproliferative activity against LT12 cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| LT12 tumor cell line | IC50 |
0.04 μM
Compound: Nocodazole
|
Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay
Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| LT12 tumor cell line | IC50 |
0.04 μM
Compound: Nocodazole
|
Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay
Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay
|
[PMID: 21705223] |
| LT12 tumor cell line | IC50 |
0.05 μM
Compound: Nocodazole
|
Antiproliferative activity against LT12 phenotype LT12 MDR tumor cell line
Antiproliferative activity against LT12 phenotype LT12 MDR tumor cell line
|
[PMID: 12852768] |
| LT12 tumor cell line | IC50 |
0.07 μM
Compound: Nocodazole
|
Antiproliferative activity against multi drug-resistant rat LT12 cells after 48 hrs by XTT assay
Antiproliferative activity against multi drug-resistant rat LT12 cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| LT12 tumor cell line | IC50 |
0.07 μM
Compound: Nocodazole
|
Antiproliferative activity against rat multiple drug-resistant LT12 cells after 48 hrs by XTT assay
Antiproliferative activity against rat multiple drug-resistant LT12 cells after 48 hrs by XTT assay
|
[PMID: 21705223] |
| LT12 tumor cell line | IC50 |
0.3 μM
Compound: Nocodazole
|
Antiproliferative activity against LT12 tumor cell line
Antiproliferative activity against LT12 tumor cell line
|
[PMID: 12852768] |
| LT12 tumor cell line | IC50 |
0.4 μM
Compound: nocodazole
|
Antiproliferative activity against rat LT12 cells ectopic expression of human MDR1 after 48 hrs by XTT assay
Antiproliferative activity against rat LT12 cells ectopic expression of human MDR1 after 48 hrs by XTT assay
|
[PMID: 19220018] |
| MCF7 | GI50 |
<0.01 μM
Compound: Nacodazole
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 31546197] |
| MCF7 | GI50 |
<0.1 μM
Compound: Nocodozole
|
Growth inhibition of human MCF7 cells by Sulforhodamine B assay
Growth inhibition of human MCF7 cells by Sulforhodamine B assay
|
[PMID: 21106458] |
| MCF7 | GI50 |
0.94 μM
Compound: 6
|
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 25131956] |
| MCF7 | GI50 |
0.94 μM
Compound: Nocodazole
|
Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 27344493] |
| MCF7 | IC50 |
0.2 μM
Compound: Ncz
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30878833] |
| MCF7 | IC50 |
0.42 μM
Compound: Nocodazole
|
Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 24 hrs by MTT assay
|
[PMID: 27496212] |
| MCF7 | IC50 |
1.086 μM
Compound: Nocodazole
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 30108815] |
| MCF7 | IC50 |
1.25 μM
Compound: Nocodazole
|
Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 28988624] |
| MCF7 | IC50 |
1.48 μM
Compound: 3
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 30108921] |
| MCF7 | IC50 |
1.5 μM
Compound: Nocodazole
|
Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 28684120] |
| MCF7 | IC50 |
1.6 μM
Compound: Nocodazole
|
Anticancer activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
|
[PMID: 26231080] |
| MCF7 | IC50 |
1.7 μM
Compound: Nocodazole
|
Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25599948] |
| MCF7 | IC50 |
1.76 μM
Compound: Nocodazole
|
Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 34095841] |
| MCF7 | IC50 |
2.37 μM
Compound: Nocodazole
|
Antiproliferative activity human MCF7 cells
Antiproliferative activity human MCF7 cells
|
[PMID: 33316752] |
| MCF7 | IC50 |
4.13 μM
Compound: NDZ
|
Anticancer activity against human MCF7 cells assessed as inhibition in cell growth measured after 72 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as inhibition in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37797804] |
| MDA-MB-231 | GI50 |
<0.01 μM
Compound: Nocodazole
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
|
[PMID: 27688193] |
| MDA-MB-231 | GI50 |
<0.01 μM
Compound: Nocodazole
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB cell proliferation assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB cell proliferation assay
|
[PMID: 29089233] |
| MDA-MB-231 | GI50 |
0.011 μM
Compound: Nacodazole
|
Antiproliferative activity against human MDA-MB-231 cells by SRB assay
Antiproliferative activity against human MDA-MB-231 cells by SRB assay
|
[PMID: 31546197] |
| MDA-MB-231 | GI50 |
0.017 μM
Compound: Nocadazole
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
|
[PMID: 25827522] |
| MDA-MB-231 | GI50 |
0.042 μM
Compound: Nocodazole
|
Anticancer activity against human MDA-MB-231 cells after 48 hrs by SRB assay
Anticancer activity against human MDA-MB-231 cells after 48 hrs by SRB assay
|
[PMID: 27130357] |
| MDA-MB-231 | GI50 |
0.065 μM
Compound: Nocodazole
|
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 28117204] |
| MDA-MB-231 | GI50 |
0.15 μM
Compound: Nocodazole
|
Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay
|
10.1039/C0MD00177E |
| MDA-MB-231 | IC50 |
<0.1 μM
Compound: Nocodazole
|
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay
|
10.1039/C0MD00263A |
| MDA-MB-231 | IC50 |
0.71 μM
Compound: 2
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 30108808] |
| MDA-MB-231 | IC50 |
1.1 μM
Compound: Nocodazole
|
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay
|
[PMID: 27496212] |
| MDA-MB-231 | IC50 |
1.38 μM
Compound: Nacodazole
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31546197] |
| MDA-MB-231 | IC50 |
1.83 μM
Compound: Nocodazole
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32717368] |
| MDA-MB-231 | IC50 |
1.862 μM
Compound: Nocodazole
|
Anticancer activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Anticancer activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 28789894] |
| MDA-MB-231 | IC50 |
1.9 μM
Compound: Nocodazole
|
Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
|
[PMID: 33316752] |
| MDA-MB-231 | IC50 |
2.37 μM
Compound: Nocodazole
|
Antiproliferative activity human MDA-MB-231 cells
Antiproliferative activity human MDA-MB-231 cells
|
[PMID: 33316752] |
| MDA-MB-453 | IC50 |
0.91 μM
Compound: Nocodazole
|
Cytotoxicity in human MDA-MB-453 cells incubated for 48 hrs by MTT assay
Cytotoxicity in human MDA-MB-453 cells incubated for 48 hrs by MTT assay
|
[PMID: 28923381] |
| MDR | IC50 |
0.07 μM
Compound: nocodazole
|
Antiproliferative activity against LT12 MDR cells by XTT assay after 48 hrs
Antiproliferative activity against LT12 MDR cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| ME-180 | IC50 |
1.7 μM
Compound: Nocodazole
|
Anticancer activity against human ME180 cells by MTT assay
Anticancer activity against human ME180 cells by MTT assay
|
10.1039/C4MD00219A |
| MIA PaCa-2 | GI50 |
0.95 μM
Compound: 6
|
Antiproliferative activity against human MIAPaCa2 cells assessed as growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human MIAPaCa2 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 25131956] |
| MIA PaCa-2 | GI50 |
0.95 μM
Compound: Nocodazole
|
Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by SRB assay
Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by SRB assay
|
[PMID: 27344493] |
| MIA PaCa-2 | IC50 |
0.91 μM
Compound: 2
|
Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 30108808] |
| MRC5 | IC50 |
15.3 μM
Compound: Ncz
|
Antiproliferative activity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30878833] |
| NCI-H460 | IC50 |
0.068 μM
Compound: Nocodazole
|
Antiproliferative activity against human NCI-H460 cells after 48 hrs by alamar blue assay
Antiproliferative activity against human NCI-H460 cells after 48 hrs by alamar blue assay
|
[PMID: 21563750] |
| NCI-H460 | IC50 |
0.15 μM
Compound: Nocodazole
|
Cytotoxic activity against cellular metabolic activity of Lung NCI-H460 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
Cytotoxic activity against cellular metabolic activity of Lung NCI-H460 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
|
[PMID: 12852768] |
| NCI-H460 | IC50 |
0.15 μM
Compound: nocodazole
|
Antiproliferative activity against NCI-H460 cells by XTT assay after 48 hrs
Antiproliferative activity against NCI-H460 cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| NCI-H460 | IC50 |
0.15 μM
Compound: nocodazole
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay
|
[PMID: 17973361] |
| NCI-H460 | IC50 |
0.15 μM
Compound: nocodazole
|
Antiproliferative activity against human NCI-H460 cells by XTT assay
Antiproliferative activity against human NCI-H460 cells by XTT assay
|
[PMID: 19220018] |
| NCI-H460 | IC50 |
0.15 μM
Compound: Nocodazole
|
Antiproliferative activity against human NCI-H460 cells after 48 hrs by XTT assay
Antiproliferative activity against human NCI-H460 cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| NCI-H460 | IC50 |
0.15 μM
Compound: Nocodazole
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay
|
[PMID: 21705223] |
| NCI-H460 | IC50 |
0.25 μM
Compound: Nocodazole
|
Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
|
[PMID: 37252100] |
| NCI-H460 | IC50 |
2.29 μM
Compound: Nocodazole
|
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 34095841] |
| P388 | IC50 |
>5 μM
Compound: nocodazole
|
Antiproliferative activity against doxorubicin-resistant mouse P388 cells expressing MDR1 protein after 48 hrs by XTT assay
Antiproliferative activity against doxorubicin-resistant mouse P388 cells expressing MDR1 protein after 48 hrs by XTT assay
|
[PMID: 19220018] |
| P388 | IC50 |
0.04 μM
Compound: nocodazole
|
Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay
|
[PMID: 19220018] |
| P388 | IC50 |
0.05 μM
Compound: nocodazole
|
Antiproliferative activity against mouse adriamycin-resistant P388 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse adriamycin-resistant P388 cells after 48 hrs by XTT assay
|
[PMID: 17973361] |
| P388 | IC50 |
0.05 μM
Compound: Nocodazole
|
Antiproliferative activity against ADR-resistant mouse P388 cells after 48 hrs by XTT assay
Antiproliferative activity against ADR-resistant mouse P388 cells after 48 hrs by XTT assay
|
[PMID: 21705223] |
| P388 | IC50 |
0.07 μM
Compound: nocodazole
|
Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay
|
[PMID: 17973361] |
| P388 | IC50 |
0.07 μM
Compound: Nocodazole
|
Antiproliferative activity against mouse P388 cells after 48 hrs by XTT proliferation assay
Antiproliferative activity against mouse P388 cells after 48 hrs by XTT proliferation assay
|
[PMID: 21705223] |
| P388 | IC50 |
0.08 μM
Compound: nocodazole
|
Antiproliferative activity against P388 cells by XTT assay after 48 hrs
Antiproliferative activity against P388 cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| P388 | IC50 |
0.08 μM
Compound: Nocodazole
|
Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| P388 | IC50 |
0.17 μM
Compound: nocodazole
|
Antiproliferative activity against P388 ADR cells by XTT assay after 48 hrs
Antiproliferative activity against P388 ADR cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| P388 | IC50 |
0.17 μM
Compound: Nocodazole
|
Antiproliferative activity against adriamycin-resistant mouse P388 cells after 48 hrs by XTT assay
Antiproliferative activity against adriamycin-resistant mouse P388 cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| P388/ADR | IC50 |
0.05 μM
Compound: Nocodazole
|
Antiproliferative activity against P388 phenotype P388 ADR tumor cell line
Antiproliferative activity against P388 phenotype P388 ADR tumor cell line
|
[PMID: 12852768] |
| P388/ADR | IC50 |
0.07 μM
Compound: Nocodazole
|
Antiproliferative activity against P388 tumor cell line
Antiproliferative activity against P388 tumor cell line
|
[PMID: 12852768] |
| PANC-1 | GI50 |
<0.01 μM
Compound: Nocadazole
|
Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay
Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay
|
[PMID: 25827522] |
| PANC-1 | GI50 |
<0.01 μM
Compound: Nocodazole
|
Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay
Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay
|
[PMID: 27688193] |
| PANC-1 | GI50 |
0.029 μM
Compound: Nocodazole
|
Anticancer activity against human PANC1 cells after 48 hrs by SRB assay
Anticancer activity against human PANC1 cells after 48 hrs by SRB assay
|
[PMID: 27130357] |
| PC-3 | IC50 |
1.84 μM
Compound: Nocodazole
|
Cytotoxicity in human PC3 cells incubated for 48 hrs by MTT assay
Cytotoxicity in human PC3 cells incubated for 48 hrs by MTT assay
|
[PMID: 28923381] |
| PC-3 | IC50 |
2.5 μM
Compound: Nocodazole
|
Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 24 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 24 hrs by MTT assay
|
[PMID: 27496212] |
| RKO | IC50 |
>10 μM
Compound: nocodazole
|
Antiproliferative activity against RKO cells with ectopic-induced p27kip1-expression by XTT assay after 48 hrs
Antiproliferative activity against RKO cells with ectopic-induced p27kip1-expression by XTT assay after 48 hrs
|
[PMID: 17181164] |
| RKO | IC50 |
>10 μM
Compound: nocodazole
|
Antiproliferative activity against human RKO cells containing ecdysone-inducible expression vector of p27kipl by XTT assay
Antiproliferative activity against human RKO cells containing ecdysone-inducible expression vector of p27kipl by XTT assay
|
[PMID: 19220018] |
| RKO | IC50 |
>10 μM
Compound: Nocodazole
|
Antiproliferative activity against human RKO cells expressing p27Kip1 after 48 hrs by XTT assay
Antiproliferative activity against human RKO cells expressing p27Kip1 after 48 hrs by XTT assay
|
[PMID: 20537765] |
| RKO | IC50 |
>10 μM
Compound: Nocodazole
|
Cytotoxic activity against human colon adenocarcinoma RKO cells with ectopic inducible expression of cyclin-dependent kinase inhibitor p27kip1
Cytotoxic activity against human colon adenocarcinoma RKO cells with ectopic inducible expression of cyclin-dependent kinase inhibitor p27kip1
|
[PMID: 12852768] |
| RKO | IC50 |
>14 μM
Compound: nocodazole
|
Cytotoxicity against human RKO cells with ectopic-inducible expression of p27kip1 after 48 hrs by XTT assay
Cytotoxicity against human RKO cells with ectopic-inducible expression of p27kip1 after 48 hrs by XTT assay
|
[PMID: 17973361] |
| RKO | IC50 |
0.11 μM
Compound: nocodazole
|
Antiproliferative activity against RKO cells by XTT assay after 48 hrs
Antiproliferative activity against RKO cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| RKO | IC50 |
0.11 μM
Compound: nocodazole
|
Cytotoxicity against human RKO cells after 48 hrs by XTT assay
Cytotoxicity against human RKO cells after 48 hrs by XTT assay
|
[PMID: 17973361] |
| RKO | IC50 |
0.11 μM
Compound: nocodazole
|
Antiproliferative activity against human RKO cells by XTT assay
Antiproliferative activity against human RKO cells by XTT assay
|
[PMID: 19220018] |
| RKO | IC50 |
0.11 μM
Compound: Nocodazole
|
Antiproliferative activity against human RKO cells after 48 hrs by XTT assay
Antiproliferative activity against human RKO cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| RKO | IC50 |
0.11 μM
Compound: Nocodazole
|
Cytotoxic activity against human colon adenocarcinoma RKO cells without ectopic inducible expression of cyclin-dependent kinase inhibitor p27kip1
Cytotoxic activity against human colon adenocarcinoma RKO cells without ectopic inducible expression of cyclin-dependent kinase inhibitor p27kip1
|
[PMID: 12852768] |
| SF-268 | IC50 |
0.3 μM
Compound: Nocodazole
|
Cytotoxic activity against cellular metabolic activity of Glioma SF-268 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
Cytotoxic activity against cellular metabolic activity of Glioma SF-268 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
|
[PMID: 12852768] |
| SF-268 | IC50 |
0.3 μM
Compound: nocodazole
|
Antiproliferative activity against SF268 cells by XTT assay after 48 hrs
Antiproliferative activity against SF268 cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| SF-268 | IC50 |
0.3 μM
Compound: nocodazole
|
Cytotoxicity against human SF268 cells after 48 hrs by XTT assay
Cytotoxicity against human SF268 cells after 48 hrs by XTT assay
|
[PMID: 17973361] |
| SF-268 | IC50 |
0.3 μM
Compound: nocodazole
|
Antiproliferative activity against human SF268 cells by XTT assay
Antiproliferative activity against human SF268 cells by XTT assay
|
[PMID: 19220018] |
| SF-268 | IC50 |
0.3 μM
Compound: Nocodazole
|
Antiproliferative activity against human SF268 cells after 48 hrs by XTT assay
Antiproliferative activity against human SF268 cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| SF-268 | IC50 |
0.3 μM
Compound: Nocodazole
|
Cytotoxicity against human SF268 cells after 48 hrs by XTT assay
Cytotoxicity against human SF268 cells after 48 hrs by XTT assay
|
[PMID: 21705223] |
| SGC-7901 | IC50 |
0.08 μM
Compound: 1
|
Growth inhibition of human SGC7901 cells after 72 hrs by MTT assay
Growth inhibition of human SGC7901 cells after 72 hrs by MTT assay
|
[PMID: 25262051] |
| SGC-7901 | IC50 |
0.085 μM
Compound: 4
|
Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
10.1039/C5MD00150A |
| SK-BR-3 | IC50 |
0.084 μM
Compound: Nocodazole
|
Growth inhibition of human SKBR3 cells after 48 hrs by MTT assay
Growth inhibition of human SKBR3 cells after 48 hrs by MTT assay
|
[PMID: 22850214] |
| SK-MEL-28 | IC50 |
8.59 μM
Compound: NDZ
|
Anticancer activity against human SK-MEL-28 cells assessed as inhibition in cell growth measured after 72 hrs by MTT assay
Anticancer activity against human SK-MEL-28 cells assessed as inhibition in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37797804] |
| SK-N-SH | GI50 |
0.65 μM
Compound: Nocodozole
|
Cytotoxicity against human SK-N-SH cells after 48 hrs by SRB assay
Cytotoxicity against human SK-N-SH cells after 48 hrs by SRB assay
|
[PMID: 20529689] |
| SK-N-SH | GI50 |
0.66 μM
Compound: Nocodozole
|
Growth inhibition of human SK-N-SH cells by Sulforhodamine B assay
Growth inhibition of human SK-N-SH cells by Sulforhodamine B assay
|
[PMID: 21106458] |
| SK-N-SH | IC50 |
<0.1 μM
Compound: Nocodazole
|
Cytotoxicity against human SK-N-SH cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human SK-N-SH cells assessed as growth inhibition after 48 hrs by SRB assay
|
10.1039/C0MD00263A |
| SK-OV-3 | IC50 |
0.08 μM
Compound: Nocodazole
|
Antiproliferative activity against human SKOV3 cells after 48 hrs by alamar blue assay
Antiproliferative activity against human SKOV3 cells after 48 hrs by alamar blue assay
|
[PMID: 21563750] |
| SK-OV-3 | IC50 |
0.17 μM
Compound: Nocodazole
|
Cytotoxic activity against cellular metabolic activity of Ovary SKOV3 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
Cytotoxic activity against cellular metabolic activity of Ovary SKOV3 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
|
[PMID: 12852768] |
| SK-OV-3 | IC50 |
0.17 μM
Compound: nocodazole
|
Antiproliferative activity against SKOV3 cells by XTT assay after 48 hrs
Antiproliferative activity against SKOV3 cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| SK-OV-3 | IC50 |
0.17 μM
Compound: nocodazole
|
Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay
Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay
|
[PMID: 17973361] |
| SK-OV-3 | IC50 |
0.17 μM
Compound: nocodazole
|
Antiproliferative activity against human SKOV3 cells by XTT assay
Antiproliferative activity against human SKOV3 cells by XTT assay
|
[PMID: 19220018] |
| SK-OV-3 | IC50 |
0.17 μM
Compound: Nocodazole
|
Antiproliferative activity against human SKOV3 cells after 48 hrs by XTT assay
Antiproliferative activity against human SKOV3 cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| SK-OV-3 | IC50 |
0.17 μM
Compound: Nocodazole
|
Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay
Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay
|
[PMID: 21705223] |
| SW480 | IC50 |
0.12 μM
Compound: Nocodazole
|
Antiproliferative activity against human SW480 cells after 48 hrs by alamar blue assay
Antiproliferative activity against human SW480 cells after 48 hrs by alamar blue assay
|
[PMID: 21563750] |
| U2OS | EC50 |
50 nM
Compound: Nocodazole
|
Induction of mitotic arrest in human U2OS cells assessed as mitotic index after 72 hrs by microscopic analysis
Induction of mitotic arrest in human U2OS cells assessed as mitotic index after 72 hrs by microscopic analysis
|
[PMID: 24900887] |
| WRL68 | IC50 |
7.56 μM
Compound: 68
|
Antiproliferative activity against human WRL68 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human WRL68 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38784470] |
| Z-138 | IC50 |
0.31 μM
Compound: Nocodazole
|
Antiproliferative activity against human Z138 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
Antiproliferative activity against human Z138 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
|
[PMID: 37252100] |
Nocodazole exhibits good affinity toward c-KIT, with a Kd value of 1.6 μM in highly malignant human cancer cells. Nocodazole displays good binding affinity toward the components of the mitogen-activated protein kinase (MAPK) pathway, such as BRAF (Kd=1.8 μM), BRAF(V600E) (Kd=1.1 μM), MEK1 (Kd=1.7 μM), and MEK2 (Kd=1.6 μM)[1]. Nocodazole has the highest affinity for αβIV and the lowest affinity for αβIII[2].
Nocodazole (1 nM) induces apoptosis of COLO 205 cancer cells[3].
Nocodazole (≥ 30 μg/mL) significantly increases the percentage of annexin-V-binding cells without significantly modifying average forward scatter of human erythrocytes[4].
In CHO cells, the addition of 1 nM Nocodazole, a concentration that suppresses microtubule dynamics, slows migration and increases the frequency and duration of resting states, but the directionality of the cells is maintained. In contrast to the effects of the low drug concentration, the addition of 70 nM Nocodazole, a concentration that eliminates the microtubule network, causes cells to move much more randomly, i.e., the directionality of the cells toward the wound is lost[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 31430-18-9
-
Appearance Solid
-
Molecular Weight 301.32
-
Formula C14H11N3O3S
-
Color Light yellow to brown
-
SMILES
O=C(OC)NC1=NC2=CC=C(C(C3=CC=CS3)=O)C=C2N1
-
Synonyms
Oncodazole; R17934
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (126)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Science
2022 Nov 18;378(6621):eabq7361. PMID: 36395215
Nocodazole purchased from MedChemExpress. Usage Cited in: Science. 2022 Nov 18;378(6621):eabq7361. [Abstract]
Representative time-lapse images (z-stack) showing microtubule nucleation after nocodazole washout in live human oocytes. Gray, microtubules (GFP-MAP4); magenta, kinetochores (mScarlet-CENPB).
Flow diagram shows the sequence of experiments. Arrow indicates timelapse imaging initiation. Time is given as hours: minutes after nocodazole washout. -
Cell
Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors. [Abstract]2025 Jun 26;188(13):3405-3421.e27. PMID: 40300601 -
Nat Methods
2022 Mar;19(3):331-340. PMID: 35228726 -
Adv Mater
Self-Sustained Biophotocatalytic Nano-Organelle Reactors with Programmable DNA Switches for Combating Tumor Metastasis. [Abstract]2025 Jan 10:e2415030. PMID: 39797479 -
Adv Mater
A Tetrahedral Framework DNA-Based Bioswitchable miRNA Inhibitor Delivery System: Application to Skin Anti-Aging. [Abstract]2022 Jul 28;e2204287. PMID: 35901292 -
Cancer Commun (Lond)
RNA m1A methyltransferase TRMT61A promotes colorectal tumorigenesis by enhancing ONECUT2 mRNA stability and is a potential therapeutic target. [Abstract]2025 Oct 16. PMID: 41103012 -
-
Sci Bull
2025 Aug 11:S2095-9273(25)00813-8. PMID: 40903356 -
Cell Mol Immunol
2020 May;17(5):496-506. PMID: 31160756 -
ACS Nano
Force-Regulated Multimotor Coordination Drives Bidirectional Lipid Droplets Transport in Tunneling Nanotubes. [Abstract]2026 Apr 21;20(15):11887-11898. PMID: 41955523 -
ACS Nano
Quantitatively Dissecting Triple Roles of Dynactin in Dynein-Driven Transport of Influenza Virus by Quantum Dot-Based Single-Virus Tracking. [Abstract]2024 Sep 17;18(37):25893-25905. PMID: 39214619 -
ACS Nano
Ligand Phase Separation-Promoted, "Squeezing-Out" Mode Explaining the Mechanism and Implications of Neutral Nanoparticles That Escaped from Lysosomes. [Abstract]2024 Jan 23;18(3):2162-2183. PMID: 38198577 -
ACS Nano
A Cancer Cell Selective Replication Stress Nano Amplifier Promotes Replication Fork Catastrophe to Overcome Radioresistance. [Abstract]2023 Sep 26;17(18):18548-18561. PMID: 37706454 -
Nat Commun
2026 Jun 8. PMID: 42259794 -
Nat Commun
Polar chromosomes are rescued from missegregation by spindle elongation-driven microtubule pivoting. [Abstract]2026 Mar 17;17(1):2049. PMID: 41844586 -
Nat Commun
2024 Nov 12;15(1):9529. PMID: 39532843 -
Nat Commun
TRABID inhibition activates cGAS/STING-mediated anti-tumor immunity through mitosis and autophagy dysregulation. [Abstract]2023 May 26;14(1):3050. PMID: 37237031
Nocodazole purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 May 26;14(1):3050. [Abstract]
Westernblot analysis of TRABID mRNA and protein levels in HeLa cells treated with 10 μM Lovastatin, 2 μg/ml Aphidicolin, 10 μM RO-3306, or 3 μM Nocodazole for 18 h.
Nocodazole purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 May 26;14(1):3050. [Abstract]
RT-qPCR analysis of TRABID mRNA and protein levels in HeLa cells treated with 10 μM Lovastatin, 2 μg/ml Aphidicolin, 10 μM RO-3306, or 3 μM Nocodazole for 18 h.
-
Nat Commun
2022 Oct 12;13(1):6004. PMID: 36224181
Nocodazole purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Oct 12;13(1):6004. [Abstract]
HEK293T cells were transfected with indicated plasmids. Eight hours later, cells were incubated with 1 μM nocodazole overnight with or without 100 μM 2-BP, washed twice with PBS, and incubated in a fresh medium for another 0.5 h. On day 0, WT or 9CS EGFR-HA-SBP was transfected with Streptavidin-Golgin-84 into HEK293T. On day 1, cells were washed with PBS and crosslinked with 2 mM DSP on ice for 2 h, which was stopped by 0.1 M Tris (pH 8.0).
-
Nat Commun
Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer. [Abstract]2019 Jun 28;10(1):2860. PMID: 31253784
Nocodazole purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Jun 28;10(1):2860. [Abstract]
Immunoblots showing cyclin profiles as well as DEDD expression of control plasmid or ∆NLS-DEDD-overexpressed normal mammary epithelial cells (KTB-37) at different time points after cells withdrawn from nocodazole treatment (100 ng/mL).
-
Cell Death Differ
The regulation loop of MARVELD1 interacting with PARP1 in DNA damage response maintains genome stability and promotes therapy resistance of cancer cells. [Abstract]2023 Apr;30(4):922-937. PMID: 36750717 -
Trends Biotechnol
Highly efficient prime editors for mammalian genome editing based on porcine retrovirus reverse transcriptase. [Abstract]2025 Aug 30:S0167-7799(25)00314-2. PMID: 40885667 -
Autophagy
2021 Dec;17(12):3976-3991. PMID: 33752561
Nocodazole purchased from MedChemExpress. Usage Cited in: Autophagy. 2021 Dec;17(12):3976-3991. [Abstract]
Immunoblot of cell lysates and anti-LC3B immunoprecipitates from U2OS cells in the absence or presence of NDZ (Nocodazole) (300 nM) treatment for 24 h followed by 24-h recovery, and cells were left untreated or treated with CQ (40 μM) treatment 8 h prior to harvesting.
Nocodazole purchased from MedChemExpress. Usage Cited in: Autophagy. 2021 Dec;17(12):3976-3991. [Abstract]
Immunofluorescent assay showing LC3B and micronuclei of WT and CGAS−/- U2OS cells left untreated or treated with NDZ (300 nM) for 24 h followed by 48-h recovery
-
Adv Sci (Weinh)
Cell Cycle Control of Nuclear Metabolism Couples Phosphatidylinositol Signaling to Histone Methylation. [Abstract]2026 Jun;13(34):e01083. PMID: 42011901 -
Adv Sci (Weinh)
Physiological pH Transition-Driven Protein Corona Dynamics Regulate Cellular Uptake and Inflammatory Responses of Silica Nanoparticles. [Abstract]2025 Sep 3:e02788. PMID: 40902197 -
Adv Sci (Weinh)
2024 Dec 4:e2408852. PMID: 39630006 -
Adv Sci (Weinh)
Unleashing the Power of Cold Atmospheric Plasma: Inducing Mitochondria Damage-Mediated Mitotic Catastrophe. [Abstract]2024 Oct 23:e2401842. PMID: 39440523
Nocodazole purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Oct 23:e2401842. [Abstract]
Representative immunofluorescent images of α‐tubulin network in Calu‐1 cells at 24 h after CAP treatment with or without Nocodazole (5 µm) treatment. Scale bar, 100 µm.
-
Adv Sci (Weinh)
The Tumor Suppressor TPD52-Governed Endoplasmic Reticulum Stress is Modulated by APCCdc20. [Abstract]2024 Dec;11(45):e2405441. PMID: 39401430
Nocodazole purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Dec;11(45):e2405441. [Abstract]
Immunoblot (IB) analysis of WCL derived from T24 and 5637 cells treated with different concentration of nocodazole (150, 300 and 900 nM) for 24 h. g‐i) IB analysis of WCL derived from mice bladder
-
Adv Sci (Weinh)
Heterogeneous Responses to Mechanical Force of Prostate Cancer Cells Inducing Different Metastasis Patterns. [Abstract]2020 Jun 17;7(15):1903583. PMID: 32775149
Nocodazole purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Jun 17;7(15):1903583. [Abstract]
Fluorescence imaging of LNCaP cells treated with the F-actin inhibitor cytoskeleton B (CB), microtubule inhibitor nocodazole (NO), FAK inhibitor PF573288 (PF), ROCK inhibitor Y-27632 (Y), and myosin II (Myo-II) inhibitor (-)-blebbistatin ((-)Bl). After the cells were cultured on different substrates for 3 days, inhibitors were added and incubated for 24 h. (green, F-actin; scale bar, 25 µm).
Nocodazole purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Jun 17;7(15):1903583. [Abstract]
Expression of CTC cluster-related (plakoglobin and CD44) and EMT-related (vimentin and E-cadherin, 4 days) proteins in LNCaP cells grown on different substrates after treatment with different inhibitors (Cytoskeleton B (CB), Nocodazole (NO), PF-573288 (PF), Y-27632 (Y), and (-)-Blebbistatin ((-) Bl)).
-
Theranostics
A Multifunctional Nanotherapy for Targeted Treatment of Colon Cancer by Simultaneously Regulating Tumor Microenvironment. [Abstract]2019 May 31;9(13):3732-3753. PMID: 31281510 -
Theranostics
Regulation of ezrin tension by S-nitrosylation mediates non-small cell lung cancer invasion and metastasis. [Abstract]2019 Apr 13;9(9):2555-2571. PMID: 31131053 -
-
Nucleic Acids Res
TriTag: an integrative tool to correlate chromatin dynamics and gene expression in living cells. [Abstract]2020 Dec 16;48(22):e127. PMID: 33104788 -
Cell Discov
2024 Nov 5;10(1):112. PMID: 39500876 -
Carbohydr Polym
Dextran-based nanodrugs with mitochondrial targeting/glutathione depleting synergy for enhanced photodynamic therapy. [Abstract]2025 Jan 15;348(Pt A):122854. PMID: 39562123 -
Redox Biol
AGR2-mediated cell-cell communication controls the antiviral immune response by promoting the thiol oxidation of TRAF3. [Abstract]2025 May:82:103581. PMID: 40085973 -
J Control Release
Intracellular redistribution of cell-penetrating peptide p28: A mechanism for enhanced anti-cancer activity. [Abstract]2025 Mar 24:113660. PMID: 40139396 -
J Control Release
Combating cisplatin-resistant lung cancer using a coiled-coil lipopeptides modified membrane fused drug delivery system. [Abstract]2025 Jan 8:379:45-58. PMID: 39756686 -
J Immunother Cancer
LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer. [Abstract]2024 Dec 18;12(12):e009444. PMID: 39694700
Nocodazole purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Dec 18;12(12):e009444. [Abstract]
Immunoblotting of whole cell lysates (WCL) derived from H292 and H1299 cells synchronized in M phase by Nocodazole (200 ng/mL; 16 h) followed by releasing back into cell cycle.
-
Mater Today Bio
Nanotube topography inhibits NLRP3 inflammasome activation by reducing microtubule glutamylation. [Abstract]2025 May 10:32:101838. PMID: 40487178 -
Cell Mol Biol Lett
Tetraspanin 3 promotes NSCLC cell proliferation via regulation of β1 integrin intracellular recycling. [Abstract]2024 Sep 27;29(1):124. PMID: 39333841 -
Cell Mol Biol Lett
Cadmium promotes nonalcoholic fatty liver disease by inhibiting intercellular mitochondrial transfer. [Abstract]2023 Oct 27;28(1):87. PMID: 37884867 -
J Neuroinflammation
α-Synuclein-containing erythrocytic extracellular vesicles: essential contributors to hyperactivation of monocytes in Parkinson's disease. [Abstract]2022 Feb 22;19(1):53. PMID: 35193594 -
Cell Death Dis
TUFT1 regulates cancer progression by suppressing centrosome amplification and mitotic spindle multipolarity. [Abstract]2025 Sep 29;16(1):673. PMID: 41022752 -
Cell Death Dis
Amyloid aggregates induced by the p53-R280T mutation lead to loss of p53 function in nasopharyngeal carcinoma. [Abstract]2024 Jan 11;15(1):35. PMID: 38212344 -
Cell Death Dis
Genome-wide screening in the haploid system reveals Slc25a43 as a target gene of oxidative toxicity. [Abstract]2022 Mar 30;13(3):284. PMID: 35354792 -
Sci China Life Sci
2025 Aug;68(8):2348-2362. PMID: 40410652 -
Cell Commun Signal
Phosphorylated IRF3 promotes GSDME-mediated pyroptosis through RIPK1/FADD/caspase-8 complex formation during mitotic arrest in ovarian cancer. [Abstract]2025 Jul 1;23(1):306. PMID: 40597187 -
Dev Cell
STAT3-controlled CHI3L1/SPP1 positive feedback loop demonstrates the spatial heterogeneity and immune characteristics of glioblastoma. [Abstract]2025 Jun 23;60(12):1751-1767.e9. PMID: 39933531 -
Int J Biol Macromol
Host factor DIAPH1 regulates pseudorabivirus replication by modulating the dynamics of cytoskeleton. [Abstract]2025 Jan 20:140112. PMID: 39842589 -
Int J Biol Macromol
Dissecting the early and late endosomal pathways of Singapore grouper iridovirus by single-particle tracking in living cells. [Abstract]2024 Jan;256(Pt 1):128336. PMID: 38013078 -
Acta Pharmacol Sin
Chromosome instability functions as a potential therapeutic reference by enhancing chemosensitivity to BCL-XL inhibitors in colorectal carcinoma. [Abstract]2024 Nov;45(11):2420-2431. PMID: 39187678 -
ACS Appl Mater Interfaces
2026 Apr 22;18(15):21500-21513. PMID: 41968920 -
ACS Appl Mater Interfaces
Intranasal Delivery of Hydrophobic AC5216 Loaded Nanoemulsion into Brain To Alleviate Chronic Unpredictable Stress-Induced Depressive-like Behaviors. [Abstract]2025 Mar 19;17(11):16533-16547. PMID: 40063900 -
Cancer Immunol Res
Discovery of podofilox as a potent cGAMP-STING signaling enhancer with antitumor activity. [Abstract]2023 May 3;11(5):583-599. PMID: 36921097 -
Free Radic Biol Med
2023 Feb 20:196:53-64. PMID: 36640852 -
Mater Sci Eng C Mater Biol Appl
RNA-seq reveals correlations between cytoskeleton-related genes and the osteogenic activity of mesenchymal stem cells on strontium loaded titania nanotube arrays. [Abstract]2021 Mar:122:111939. PMID: 33641927 -
NPJ Precis Oncol
Targeting high-risk MYC-overexpressed osteosarcoma with an Aurora kinase inhibitor:--results from a pilot umbrella trial. [Abstract]2025 Dec 10. PMID: 41372533 -
ACS Environ Au
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]2025 Aug 5;5(6):573-582. PMID: 41277996 -
Genes Dev
USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer. [Abstract]2021 Oct 1;35(19-20):1327-1332. PMID: 34531315 -
Biomed Pharmacother
Drug target proteome profiling identifies HES1-driven mitotic catastrophe in ovarian serous carcinoma. [Abstract]2025 Nov 6:193:118716. PMID: 41202420 -
Biomed Pharmacother
Wee1 inhibition by MK1775 potentiates gemcitabine through accumulated replication stress leading to apoptosis in biliary tract cancer. [Abstract]2023 Oct:166:115389. PMID: 37659202 -
Int Endod J
2026 Jun 2. PMID: 42227345 -
Aging Cell
p62/SQSTM1 Condensation Modulates Mitochondrial Clustering to Participate in Mitochondrial Quality Control. [Abstract]2026 Feb;25(2):e70402. PMID: 41674118 -
Int Endod J
Electric field promoted odontogenic differentiation of stem cells from apical papilla by remodelling cytoskeleton. [Abstract]2025 Apr 1. PMID: 40170340 -
Cell Rep
Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis. [Abstract]2024 Jul 3;43(7):114431. PMID: 38968071 -
Cell Rep
DHHC4 and DHHC5 Facilitate Fatty Acid Uptake by Palmitoylating and Targeting CD36 to the Plasma Membrane. [Abstract]2019 Jan 2;26(1):209-221.e5. PMID: 30605677 -
Clin Transl Med
Pathogenic variants of TUBB8 cause oocyte spindle defects by disrupting with EB1/CAKP5 interactions and potential treatment targeting microtubule acetylation through HDAC6 inhibition. [Abstract]2025 Jan;15(1):e70193. PMID: 39834092 -
Anal Chem
Developing Quinacridone-Based Long Fluorescent Lifetime Probes for Cell Membrane Heterogeneity Imaging. [Abstract]2025 Oct 28;97(42):23251-23259. PMID: 41039728 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Anal Chem
Metabolic Footprinting-Based DNA-AuNP Encoders for Extracellular Metabolic Response Profiling. [Abstract]2023 May 23;95(20):8088-8096. PMID: 37155931 -
Sci Signal
The kinase PLK1 promotes Hedgehog signaling-dependent resistance to the antiandrogen enzalutamide in metastatic prostate cancer. [Abstract]2025 Mar 18;18(878):eadi5174. PMID: 40100956 -
J Cell Biol
ER-derived caveolin-coated vesicles transport newly synthesized cholesterol to the plasma membrane. [Abstract]2026 Jun 1;225(6):e202502001. PMID: 41973050 -
Cell Biosci
2023 Nov 25;13(1):215. PMID: 38007480 -
JCI Insight
Germline mutations in a DNA repair pathway are associated with familial colorectal cancer. [Abstract]2021 Sep 22;6(18):e148931. PMID: 34549727 -
Cell Prolif
The S-Phase Arrest of Host Cells Caused by an Alpha-Herpesvirus Genome Replication Facilitates Viral Recruitment of RNA Polymerase II to Transcribe Viral Genes. [Abstract]2025 Jan 27:e13811. PMID: 39870514 -
Pharmaceutics
Transport Mechanisms of Polymannuronic Acid and Polyguluronic Acid Across Caco-2 Cell Monolayers. [Abstract]2020 Feb 17;12(2):167. PMID: 32079270 -
PLoS Pathog
Probing the spatiotemporal patterns of HBV multiplication reveals novel features of its subcellular processes. [Abstract]2021 Aug 9;17(8):e1009838. PMID: 34370796 -
Int Immunopharmacol
IQGAP1 domesticates macrophages to favor mycobacteria survival via modulating NF-κB signal and augmenting VEGF secretion. [Abstract]2024 Jun 29:138:112549. PMID: 38944950 -
Mol Cancer Res
Overlaid Transcriptional and Proteome Analyses Identify Mitotic Kinesins as Important Targets of Arylsulfonamide-Mediated RBM39 Degradation. [Abstract]2023 Aug 1;21(8):768-778. PMID: 37255411 -
J Mol Cell Cardiol
Defective autophagy triggered by arterial cyclic stretch promotes neointimal hyperplasia in vein grafts via the p62/nrf2/slc7a11 signaling pathway. [Abstract]2022 Dec:173:101-114. PMID: 36308866 -
Bioelectrochemistry
Moderate intensity static magnetic fields affect mitotic spindles and increase the antitumor efficacy of 5-FU and Taxol. [Abstract]2016 Jun:109:31-40. PMID: 26775206 -
Mol Nutr Food Res
Diallyl Trisulfide, A Major Bioactive Constituent Of The Garlic, Promotes Colonic Mucosal Healing In Ulcerative Colitis Through Accelerating Focal Adhesion Assembly And Consequent Epithelial Cell Migration Via The Rab21-Integrin Β1-Fak Pathway. [Abstract]2023 Jun;67(12):e2200784. PMID: 36938915 -
J Cell Mol Med
TBC1 domain family member 23 interacts with Ras-related protein Rab-11A to promote poor prognosis of non-small-cell lung cancer via β1-integrin. [Abstract]2021 Sep;25(18):8821-8835. PMID: 34363324 -
J Cell Mol Med
Bioinformatic analysis and validation of microRNA-508-3p as a protective predictor by targeting NR4A3/MEK axis in pulmonary arterial hypertension. [Abstract]2021 Jun;25(11):5202-5219. PMID: 33942991 -
iScience
2026 Mar 4;29(4):115223. PMID: 41890968 -
AAPS PharmSciTech
Transcellular Transport Behavior of the Intact Polymeric Mixed Micelles with Different Polymeric Ratios. [Abstract]2023 Feb 15;24(2):69. PMID: 36792796 -
J Dermatol Sci
2022 Jun;106(3):181-188. PMID: 35637111 -
J Virol
Spike proteins of coronaviruses activate mast cells for degranulation via stimulating Src/PI3K/AKT/Ca2+ intracellular signaling cascade. [Abstract]2025 Apr 30:e0007825. PMID: 40304504 -
Reproduction
2026 Jan 15;171(1):xaaf013. PMID: 41575147 -
Chemistry
DNA Tetrahedron-Enhanced Catalytic Hairpin Assembly for in Situ Monitoring of Viral RNA in Host Cells. [Abstract]2025 May 23:e202501329. PMID: 40407343 -
Food Chem Toxicol
Carbendazim exposure inhibits mouse oocytes meiotic maturation in vitro by destroying spindle assembly. [Abstract]2023 Sep:179:113966. PMID: 37506866 -
Cell Cycle
A novel function of anaphase promoting complex subunit 10 in tumor progression in non-small cell lung cancer. [Abstract]2019 May;18(9):1019-1032. PMID: 31023143 -
Biochim Biophys Acta Mol Cell Biol Lipids
Cytoskeleton regulates lipid droplet fusion and lipid storage by controlling lipid droplet movement. [Abstract]2025 Apr 4:159610. PMID: 40189192 -
J Cancer
Sinapine Thiocyanate Inhibits the Proliferation and Mobility of Pancreatic Cancer Cells by Up-Regulating GADD45A. [Abstract]2022 Jan 24;13(4):1229-1240. PMID: 35281859 -
Hum Mol Genet
E3 ligase Smurf1 protects against misfolded SOD1 in neuronal cells by promoting its K63 ubiquitylation and aggresome formation. [Abstract]2022 Jun 22;31(12):2035-2048. PMID: 35022748 -
Front Biosci (Landmark Ed)
HP1 Promotes the Centromeric Localization of ATRX and Protects Cohesion by Interfering Wapl Activity in Mitosis. [Abstract]2025 Jan 21;30(1):26426. PMID: 39862081 -
Toxicol In Vitro
Triphenyltin chloride exposure inhibits meiotic maturation of mouse oocytes by disrupting cytoskeleton assembly and cell cycle progression. [Abstract]2024 Jun:98:105834. PMID: 38657713 -
Virus Res
Muscovy duck reovirus enters susceptible cells via a caveolae-mediated endocytosis-like pathway. [Abstract]2020 Jan 15;276:197806. PMID: 31704247 -
PLoS One
2019 Jul 3;14(7):e0210377. PMID: 31269031 -
Dig Dis Sci
TET2 Is Downregulated in Early Esophageal Squamous Cell Carcinoma and Promotes Esophageal Squamous Cell Malignant Behaviors. [Abstract]2024 Jul;69(7):2462-2476. PMID: 38653944 -
Biochem Biophys Res Commun
Sevoflurane preconditioning improves Cx43 localization and electrical conduction by stabilizing myocardial microtubule structure during ischemia-reperfusion. [Abstract]2025 Sep 30:782:152552. PMID: 40902546 -
J Mol Histol
The role of RAP2 in regulation of cell volume on bone marrow mesenchymal stem cell fate determination. [Abstract]2025 Feb 4;56(2):79. PMID: 39903386 -
Biochem Biophys Res Commun
Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities. [Abstract]2020 Feb 19;522(4):862-868. PMID: 31806372 -
Biol Open
2019 Aug 15;8(8):bio041293. PMID: 31362949 -
-
-
bioRxiv
2025 Sep 18:2025.09.17.676776. PMID: 41000743 -
-
-
bioRxiv
2025 Jun 17:2025.06.16.659978. PMID: 40667017 -
-
bioRxiv
Pharmacological inhibition of host pathways enhances macrophage killing of intracellular bacterial pathogens. [Abstract]2025 Apr 7:2025.04.06.647500. PMID: 40291742 -
-
bioRxiv
Multiple interactions mediate the localization of BLTP2 at ER-PM contacts to control plasma membrane dynamics. [Abstract]2025 Feb 8:2025.02.07.637094. PMID: 39974967 -
bioRxiv
RBN-2397, a PARP7 Inhibitor, Synergizes with Paclitaxel to Inhibit Proliferation and Migration of Ovarian Cancer Cells. [Abstract]2024 Aug 21:2024.08.20.608802. PMID: 39229139 -
-
bioRxiv
Interpretable representation learning for 3D multi-piece intracellular structures using point clouds. [Abstract]2024 Jul 27:2024.07.25.605164. PMID: 39091871 -
-
-
-
-
-
-
-
Solvent & Solubility
DMSO : 16.67 mg/mL (55.32 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.90 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2 mg/mL (6.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 5 mg/mL (16.59 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Proteins are loaded at 50 μg/lane and separated by 12% (w:v) sodium dodecyl sulfate-polyacrylamide gel electrophoresis, blotted, and probed with antibodies for cyclin E, p53, p21/CIP1, p27/KIP1, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), cyclin A, cyclin D1, cyclin D3, cyclin B, CDK2, CDK4, and cytochrome C. Immunoreactive bands are visualized by incubating with the colorigenic substrates nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate. The expression of GAPDH is used as the control for equal protein loading.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
COLO 205 cells are grown in RPMI 1640 supplemented with 10% FCS. Cells are harvested through two consecutive trypsinizations, centrifuged at 300×g; for 5 min, washed twice, and resuspended in sterile phosphate-buffered saline (PBS). Cells (5×105) in 0.1 mL are injected subcutaneously between the scapulae of each nude mouse. After transplantation, tumor size is measured with calipers, and the tumor volume is estimated. Once tumors reach a mean size of 200 mm3, animals receive intraperitoneal injections of DMSO (25 μL), R-41400 (50 mg/kg), nocodazole (5 mg/kg), or R-41400 + nocodazole three times per week for 6 wk.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Park H, et al. Nocodazole is a high-affinity ligand for the cancer-related kinases ABL, c-KIT, BRAF, and MEK. ChemMedChem. 2012 Jan 2;7(1):53-6. [Content Brief]
[2]. Keliang Xu, et al. Interaction of nocodazole with tubulin isotypes. Drug Development Research 2002
[3]. Wang YJ, et al. R-41400 potentiates the antitumor effects of nocodazole: In vivo therapy for human tumor xenografts in nude mice. Mol Carcinog. 2002 Aug;34(4):199-210. [Content Brief]
[4]. Signoretto E, et al. Nocodazole Induced Suicidal Death of Human Erythrocytes. Cell Physiol Biochem. 2016;38(1):379-92. [Content Brief]
[5]. Zhang JP, et al. Efficient precise knockin with a double cut HDR donor after CRISPR/Cas9-mediated double-stranded DNA cleavage. Genome Biol. 2017 Feb 20;18(1):35. [Content Brief]
[6]. Anutosh Ganguly, et al. The role of microtubules and their dynamics in cell migration. J Biol Chem. 2012 Dec 21;287(52):43359-69. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3187 mL | 16.5937 mL | 33.1873 mL | 82.9683 mL |
| 5 mM | 0.6637 mL | 3.3187 mL | 6.6375 mL | 16.5937 mL | |
| 10 mM | 0.3319 mL | 1.6594 mL | 3.3187 mL | 8.2968 mL | |
| 15 mM | 0.2212 mL | 1.1062 mL | 2.2125 mL | 5.5312 mL | |
| 20 mM | 0.1659 mL | 0.8297 mL | 1.6594 mL | 4.1484 mL | |
| 25 mM | 0.1327 mL | 0.6637 mL | 1.3275 mL | 3.3187 mL | |
| 30 mM | 0.1106 mL | 0.5531 mL | 1.1062 mL | 2.7656 mL | |
| 40 mM | 0.0830 mL | 0.4148 mL | 0.8297 mL | 2.0742 mL | |
| 50 mM | 0.0664 mL | 0.3319 mL | 0.6637 mL | 1.6594 mL |